Home Study finds key GSK-Theravance lung drug didn't extend lives
 

Keywords :   


Study finds key GSK-Theravance lung drug didn't extend lives

2015-09-09 01:33:31| Biotech - Topix.net

A closely watched study of GlaxoSmithKline plc's Breo Ellipta respiratory treatment failed to prove that it extends patients' lives, denying the drugmaker a much-needed marketing edge in its most lucrative - but declining - medicine category. It was a disappointing deja vu for the British drugmaker, which previously failed to prove the same benefit for its much older respiratory treatment Advair, long the company's top seller with revenue of $8.3 billion as recently as 2013.

Tags: key study lives drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
14.1115kg 50mm
14.11ONE PIECE BOX
14.11DAIWA OCEAN STAR 500
14.11fender jhon mayer blackone
14.11 Angel Touch Plus vol.3
14.11Strymon BigSky
14.11
14.11 TOUR B X 2
More »